NCT00596297View on ClinicalTrials.gov

Preoperative Bevacizumab for Vitreous Hemorrhage

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Diabetic RetinopathyVitreous Hemorrhage
Interventions
DRUG

bevacizumab

Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline

PROCEDURE

pars plana vitrectomy

4 weeks after baseline

Trial Locations (1)

14049-900

Clinics Hospital of Ribeirão Preto, School of Medicine of Ribeirão Preto, USP, Ribeirão Preto

All Listed Sponsors
lead

University of Sao Paulo

OTHER

NCT00596297 - Preoperative Bevacizumab for Vitreous Hemorrhage | Biotech Hunter | Biotech Hunter